Petitioning U.S. House of Representatives and 2 others

LYME DISEASE PATIENT LIVES SACRIFICED IN FAVOR OF LYME VACCINE AGENDA

2,185
Supporters

THE CDC-SANCTIONED DEARBORN TWO-TIER TESTING CRITERIA AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA LYME TREATMENT GUIDELINES CAUSE WIDESPREAD SUFFERING FOR PATIENTS WITH PERSISTENT MANIFESTATIONS OF LYME DISEASE. THESE HAVE BEEN IMPLEMENTED TO ACCOMMODATE VACCINE APPROVAL WHILE CAUSING WIDESPREAD DAMAGE AND SUFFERING TO PATIENTS.

Letter to
U.S. House of Representatives
U.S. Senate
President of the United States
We, the undersigned, DECLARE that the Dearborn two-tier testing criteria sanctioned by CDC, along with the Infectious Diseases Society of America’s Practice Guidelines for the Treatment of Lyme Disease are obstacles to public health and the testing criteria and treatment guidelines have been promoted by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA), despite these entities being made aware over a period of many years, that the testing criteria and treatment guidelines are inadequate in managing the complicated and serious manifestations of Borrelia burgdorferi infection (Lyme disease).

We, the undersigned, DECLARE that the above-referenced testing criteria and treatment guidelines have been implemented to accommodate vaccine development, vaccine clinical trials, vaccine approval and vaccine marketing, resulting in the medical neglect of a large and expanding patient population already infected with Borrelia burgdorferi (Lyme disease).

We, the undersigned, DECLARE that we object to all Lyme disease vaccine development, clinical trials, approval and marketing as long as the success of potential Lyme vaccines depends upon the Dearborn two-tier testing criteria and/or the IDSA Practice Guidelines for Lyme Disease, as implementation of the Dearborn two-tier testing criteria and the IDSA Practice Guidelines for Lyme Disease have caused years of widespread medical neglect and suffering of a large and expanding patient population already infected with Borrelia burgdorferi (Lyme disease). Patients refuse to allow their lives to be sacrificed for the sake of vaccine development and approval.

We, the undersigned, DEMAND that the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA) immediately acknowledge publicly and conspicuously post on their websites their acknowledgment of established, published scientific evidence of the persistence of Borrelia burgdorferi (Lyme disease) infection post antibiotic therapy, as evidenced in published scientific research.

We, the undersigned, DEMAND that CDC immediately disseminate to physicians worldwide in its MMWR their acknowledgement of the existence of persistent infection despite antibiotic therapy, as evidenced in published scientific research.

We, the undersigned, DEMAND that the Infectious Diseases Society of America update their Practice Guidelines for Lyme Disease to adequately and meaningfully reflect the existence of persistent infection post antibiotic therapy, as evidenced by published scientific research.

We, the undersigned, DEMAND that CDC remove from its website and disseminated materials all references to the IDSA Practice Guidelines for Lyme Disease until the IDSA has updated its Practice Guidelines for Lyme Disease to adequately and meaningfully reflect the existence of persistent infection post antibiotic therapy, as evidenced by published scientific research.

We, the undersigned, DEMAND that CDC and IDSA conspicuously post the following on their websites and disseminate the following statement in information to physicians and IDSA members:

TO DATE, NO 100% EFFECTIVE TREATMENT PROTOCOL FOR LYME DISEASE HAS BEEN DEVELOPED BY THE NATIONAL INSTITUTES OF HEALTH, THE CENTERS FOR DISEASE CONTROL AND PREVENTION OR THE INFECTIOUS DISEASES SOCIETY OF AMERICA. UNTIL SUCH A TREATMENT PROTOCOL IS DEVELOPED AND PROVEN TO BE 100% EFFECTIVE IN ERADICATING THE INFECTION AND SYMPTOMS, PHYSICIANS MUST USE THEIR BEST CLINICAL JUDGMENT IN DIAGNOSING AND RENDERING TREATMENT TO PATIENTS, WITH PATIENT HEALTH AND SAFETY DURING TREATMENT TO REMAIN AT THE FOREFRONT OF PHYSICIAN TREATMENT DECISIONS.